There's nothing like a good physical examination Temporal artery exam & ultrasound vs temporal artery biopsy n=97 consecutive ?GCA pts from Carlo Salvarini's group Very decent PPV Those TA exam findings can be hard to find, but they're gold dust. POS0820 #EULAR2022 @RheumNow https://t.co/X9TzIqQBaB

#EULAR2022 POS0213 Beware of paradoxical low lipids in RA! ⭐️ETN+MTX vs MTX T2T: Early ETN: increased in HLD, lesser LDL, differs from MTX. Correlates with clinical disease activity @RheumNow https://t.co/c6GXadVwYN

SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn

Dr Patel @NaomiRheumMD et al. Avacopan in AAV at different thresholds toxicity. Minimum clinically important difference for GTI is 10 points. Avacopan assoc lower glucocorticoid toxicity irrespective of threshold used. @RheumNow #EULAR2022 POS0833 https://t.co/8iIIAsMOlI

Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bisphosphonate in bone group 60% vs 6%. Better response to DMARD in joint/mixed group 94% vs 40% @RheumNow #EULAR2022 POS1333 https://t.co/FfYBIEGGgJ

#EULAR2022 POS0207 Fatigue in early RA: ⭐️Does not show direct effect between inflammation on fatigue ⭐️Suggests broader indirect effect of psychosocial aspects of wellbeing (pain, mental health, sleep, disease perception) plays larger role @Rheumnow https://t.co/zTxk7kZRIX

Szekanecz et al. ORAL Surveillance. Geographic differences in MACE largely driven by history CVD and high baseline risk in North America and ROW. @RheumNow #EULAR2022 POS0110 https://t.co/cR6a7N2KP5

Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generally stopped due to remission, 10% stopped due to adverse event @RheumNow #EULAR2022 POS0267 https://t.co/jlZDTinfCK

The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al

For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound? PsO pts with MSK pain n=79 USS inflamm in 47% Site-spec correlate only OR 3.1 Even if we act on USS: PsA Rx is systemic, so overall impression is good enough anyway? POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw

Are wearable devices useful in assessing physical activity in rheumatic diseases? Meta-analysis showed pts with rheumatic diseases reached recommended threshold for moderate to vigorous physical activity but not daily steps. @RheumNow #EULAR2022 POST#POS0163

Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw

OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF